Brind.
  1. Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.
  2. Sanofi, Regeneron, and Bayer are involved in new market developments, including FDA submissions regarding eczema and eye care treatments.

Sanofi and Regeneron Split Dupixent Profits, Driving Regeneron's Q3 Surge

1 report, 1 independent Updated Fri 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Sanofi and Regeneron Pharmaceuticals expanded their antibody alliance and agreed to split profits from Dupixent. According to reports, Dupixent’s global net sales, recorded by Sanofi, rose 35% to $6.5 billion. This collaboration revenue for Regeneron jumped 68% to $2,724 million, and Sanofi recovered a development balance previously advanced for shared research.

From 247wallst.com

Why it matters

Some supportBrind's analysis of the reports

The partnership arrangement was cited as the primary driver of Regeneron Pharmaceuticals' strong third quarter. The company reported Q3 2026 revenue of $5.1 billion, a 36% increase year over year, and adjusted earnings per share climbed 70% to $20.07.

Major pharmaceutical companies, including Sanofi and Regeneron Pharmaceuticals, are maintaining alliances and competing across key therapeutic areas such as immunology and ophthalmology.

From 247wallst.com

Who's involved

  • SanofiFrench pharmaceutical company that sells Dupixent worldwide and shares profits with Regeneron Pharmaceuticals.
  • Regeneron PharmaceuticalsAmerican pharmaceutical company that shares Dupixent profits with Sanofi and expanded its antibody alliance.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • Regeneron PharmaceuticalsSpeculative

    Regeneron Pharmaceuticals might see increased revenue and investment due to the profit split and expanded alliance with Sanofi.

Possible ripples

Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.

Keep exploring

Part of

Sanofi, Regeneron, and Bayer are involved in new market developments, including FDA submissions regarding eczema and eye care treatments.

Also in this story

All 3 developments

Within Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.

The entities involved

Related events

Coverage

Newest first; wire copies grouped